1-benzo[b]thiophen-3-ylmethyl-piperidine | 95770-54-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 1-benzo[b]thiophen-3-ylmethyl-piperidine
• 英文别名: 3-Piperidinomethyl-benzo thiophen；3-Piperidinomethyl-benzothiophen；1-(1-Benzothien-3-ylmethyl)piperidine；1-(1-benzothiophen-3-ylmethyl)piperidine
• CAS: 95770-54-0
• 化学式: C₁₄H₁₇NS
• 分子量: 231.362
• InChiKey: JKRKLHWYSPAZAT-UHFFFAOYSA-N

物化性质

• 沸点：
  346.5±17.0 °C(Predicted)
• 密度：
  1.160±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  31.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-benzo[b]thiophen-3-ylmethyl-piperidine 在 sodium tetrahydroborate 、 正丁基锂 作用下， 以 乙醇 为溶剂， 反应 0.5h， 生成 [3-(Piperidin-1-ylmethyl)-1-benzothiophen-2-yl]methanol
  参考文献：
  名称：

  Structure-activity relationships of a series of benzothiophene-derived NPY Y1 antagonists: Optimization of the C-2 side chain

  摘要：

  A series of benzo[b]thiophene-derived NPY-1 receptor antagonists is described. Systematic modification of the C-2 substituent afforded a 1000-fold range in Y1 receptor affinity. Appropriate substitution at the ortho and para positions of the C-2 phenyl ether produced a synergistic effect on Y1 binding affinity, which led to the discovery of the most active ligands, 12t (K-i = 15 nM), 12u (K-i = 11 nM), and 12v (K-i = 13 nM). (C) 1999 Elsevier Science Ltd. An rights reserved.

  DOI：

  10.1016/s0960-894x(99)00019-0
• 作为产物：
  描述：

  哌啶 、 2-氯-3-甲基苯并(b)噻吩 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 生成 1-benzo[b]thiophen-3-ylmethyl-piperidine
  参考文献：
  名称：

  Structure-activity relationships of a series of benzothiophene-derived NPY Y1 antagonists: Optimization of the C-2 side chain

  摘要：

  A series of benzo[b]thiophene-derived NPY-1 receptor antagonists is described. Systematic modification of the C-2 substituent afforded a 1000-fold range in Y1 receptor affinity. Appropriate substitution at the ortho and para positions of the C-2 phenyl ether produced a synergistic effect on Y1 binding affinity, which led to the discovery of the most active ligands, 12t (K-i = 15 nM), 12u (K-i = 11 nM), and 12v (K-i = 13 nM). (C) 1999 Elsevier Science Ltd. An rights reserved.

  DOI：

  10.1016/s0960-894x(99)00019-0

文献信息

• [EN] FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS<br/>[FR] DÉRIVÉS CONDENSÉS DE PYRAZOLE UTILISÉS COMME NOUVEAUX INHIBITEURS ERK
  申请人：SCHERING CORP

  公开号：WO2012036997A1

  公开（公告）日：2012-03-22

  Disclosed are the ERK inhibitors of Formula (I): (Formula (I)) and the pharmaceutically acceptable salts thereof. All substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of Formula (I).

  公开了化学式（I）的ERK抑制剂：（化学式（I））及其药学上可接受的盐。所有取代基如本文所定义。还公开了使用化合物（I）治疗癌症的方法。
• [EN] NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS COMME INHIBITEURS DE ERK
  申请人：MERCK SHARP & DOHME

  公开号：WO2011163330A1

  公开（公告）日：2011-12-29

  The present invention provides a compound of the Formula I:(Formular I should be inserted here) or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R, R1, R2 and R3 are as defined herein. The compounds are ERK inhibitors. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.

  本发明提供了一种化合物，其化学式为I：（此处应插入化学式 I），或其药用可接受的盐、溶剂或酯，其中 R、R1、R2 和 R3 如本文所定义。这些化合物是 ERK 抑制剂。还公开了包括上述化合物的药物组合物以及使用它们治疗癌症的方法。
• NOVEL COMPOUNDS THAT ARE ERK INHIBITORS
  申请人：MERCK SHARP & DOHME CORP.

  公开号：EP3536319A1

  公开（公告）日：2019-09-11

  Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof, wherein: A is a five membered monocyclic heteroaryl ring; and B is a monocyclic heterocycloalkyl ring, or a monocyclic heterocycloalkenyl ring, or a bridged monocyclic heterocycloalkyl ring, or a fused (monocyclic heterocycloalkyl ring)cyclopropyl ring. Also disclosed are methods of treating cancer using the compounds of formula (1).

  所公开的是式 (1) 的 ERK 抑制剂： 及其药学上可接受的盐类，其中A 是五元单环杂芳基环；B 是单环杂环烷基环、或单环杂环烯基环、或桥接单环杂环烷基环、或融合（单环杂环烷基环）环丙基环。还公开了使用式（1）化合物治疗癌症的方法。
• [EN] NOVEL COMPOUNDS THAT ARE ERK INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS QUI SONT DES INHIBITEURS DE ERK
  申请人：SCHERING CORP

  公开号：WO2012058127A2

  公开（公告）日：2012-05-03

  Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof, wherein: A is a five membered monocyclic heteroaryl ring; and B is a monocyclic heterocycloalkyl ring, or a monocyclic heterocycloalkenyl ring, or a bridged monocyclic heterocycloalkyl ring, or a fused (monocyclic heterocycloalkyl ring)cyclopropyl ring. Also disclosed are methods of treating cancer using the compounds of formula (1).
• Structure-activity relationships of a series of benzothiophene-derived NPY Y1 antagonists: Optimization of the C-2 side chain
  作者：Thomas C. Britton、Patrick G. Spinazze、Philip A. Hipskind、Dennis M. Zimmerman、Hamideh Zarrinmayeh、Douglas A. Schober、Donald R. Gehlert、Robert F. Bruns

  DOI：10.1016/s0960-894x(99)00019-0

  日期：1999.2

  A series of benzo[b]thiophene-derived NPY-1 receptor antagonists is described. Systematic modification of the C-2 substituent afforded a 1000-fold range in Y1 receptor affinity. Appropriate substitution at the ortho and para positions of the C-2 phenyl ether produced a synergistic effect on Y1 binding affinity, which led to the discovery of the most active ligands, 12t (K-i = 15 nM), 12u (K-i = 11 nM), and 12v (K-i = 13 nM). (C) 1999 Elsevier Science Ltd. An rights reserved.